Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NADH:ubiquinone oxidoreductase subunit B10 pseudogene 2 (NDUFB10P2) is a pseudogene annotated in several genomic databases. Pseudogenes are segments of DNA resembling known genes but rendered nonfunctional by mutations; they typically do not encode active protein products. However, emerging research shows that some pseudogenes can be transcribed into RNA and may play a regulatory role, such as modulating expression of their parent gene through mechanisms like competing endogenous RNAs (ceRNAs) or serving as microRNA decoys. Despite this, there is currently no evidence that NDUFB10P2 itself acts as a functional regulator or is directly involved in human disease, nor is it targeted by any therapeutics. Key points: - This entry is a pseudogene, not a protein, receptor, or enzyme. - It is not considered a canonical drug target. - Any functional effects would be indirect and hypothetical, reflecting general features of pseudogenes rather than something known for NDUFB10P2 itself.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NADH:ubiquinone oxidoreductase subunit B10 pseudogene 2 (NDUFB10P2).